Case report shows cerebrospinal fluid penetration of sulbactam-durlobactam in ventriculitis, suggesting monitoring improvements.
Two adult patients with ventriculitis due to Acinetobacter baumannii were treated with intravenous sulbactam-durlobactam as a part of a combination regimen. Penetration into the central nervous system was estimated (by cerebrospinal fluid [CSF]/serum area under the curve [AUC] ratios at steady state) for sulbactam (0.47–0.64) and durlobactam (0.27–0.3), respectively. In view of mostly constant CSF concentrations, single CSF levels at steady state may offer a more convenient and clinically applicable approach for monitoring therapy.
No takes yet. Share an insight, caveat, or question.
Pouya et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: